VolitionRx Limited, a global epigenetics company, based in Henderson, Nevada, made an announcement on July 7, 2026, revealing the results of a recent clinical study. The study highlighted the remarkable prognostic capability of its Nu.Q® Cancer Assay specifically for newly diagnosed lung cases. This breakthrough can potentially revolutionize cancer diagnosis and treatment. The company, listed on NYSE American under the ticker symbol VNRX, is gaining attention for its innovative approach to healthcare.